2005 Fiscal Year Final Research Report Summary
Investigation of Vasohibin as Negative Feedback Molecule of Angiogenesis in Clinical Lung Cancer.
| Project/Area Number |
16591382
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
MATSUMURA Yuji Tohoku University, Institute of Development, Aging and Cancer, Associate Professor, 加齢医学研究所, 助教授 (80281997)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KONDO Takashi Tohoku University, Institute of Development, Aging and Cancer, Professor, 加齢医学研究所, 教授 (10195901)
SUZUKI Satoshi Tohoku University, Hospital, Lecturer, 病院・講師 (50344669)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Keywords | Vasohibin / Non small cell lung cancer / Angiogenesis |
|---|
| Research Abstract |
We studied Vasohibin as a new suppressor molecule of angiogenesis in clinical non-small cell lung cancer. We examined serum concentration of Vasohibin by Western blotting method and histoimmunochemical stains (Vasohibin, VEGF, and HIF1a) of resected lung tumors of non-small cell lung cancer in 44 surgical cases.
Vasohibin was stained positive in CD31 positive cells and not stained in Podoplanin (indicator of lymph vessels) positive cells. This finding suggests Vasohibin might be expressed in endothelium. There were some correlations between CD30 positive and VEGF expression (negative : 0.44 vs. positive : 0.61, p<0.01) or HIFa(negative : 0.37 vs. positive : 0.58, p<0.01) in lung cancer tissues. The expressions of VEGF and HIFa in lung samples were identical in 30/44 cases. The correlation was not detected between density of small vessels and Vasohibin positive in lung cancer tissue.
Vasohibin protein was measurable in blood samples in 37/44 (84%) cases. Vasohibin positive cases in serum were also more positive in lung cancer tissue (positive : 0.56 vs. negative : 0.36, p<0.01). Vasohibin concentration in serum should be a reflection of amounts of lung cancer tissue. In the future, Vasohibin will be able to use as new tumor maker of non-small cell lung cancer.
|
